Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Many patients on Highly Active Antiretroviral Therapy (HAART) are able to achieve a sustained
response with viral loads becoming undetectable and staying undetectable, but do not have an
increase in their CD4 counts to levels greater than 500. Adding maraviroc to the treatment
regimen of these patients may result in an increase in their CD4 counts. As the patient would
be continuing their prior regimen, they will likely continue with full control of viral
replication.
Phase:
N/A
Details
Lead Sponsor:
Southern California Institute for Research and Education